Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.
Capitol Hill: With money tight, support for 2015 goal is symbolic.
Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.
NCI selects nanotech centers for funding.
Trending Stories
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - In the Headlines: Missing record of NCAB meetings restored to NIH website
- Insights from ASCO 2025: Real-world evidence drives clinical decision-making
- In first NCAB meeting since Trump’s inauguration, Lowy reflects on funding choices in lean times
“In the NCI director’s office, we have a photograph of a stone bridge, and it asks the question, which stone holds up the bridge? And the answer is all of them.”